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Introduction: The International Registry of Lung Metastases de-
fined a new staging system based on identified prognostic factors for
long-term survival after metastasectomy. The aim of our study was
to confirm the validity of the International Registry of Lung Metas-
tases classification system in patients who underwent curative lung
metastasectomy in a single center.
Methods:We retrospectively reviewed 575 patients who underwent
708 lung metastasectomies from January 1998 to October 2008.
Complete curative pulmonary resections were performed in 490
cases (85%). Three hundred seventy-two patients developed lung
metastases from epithelial tumors, 80 from sarcomas, 27 from
melanomas, and 11 from germ cell tumors. The mean disease-free
interval (DFI) was 46.6 months. Open surgical resection was per-
formed in 479 patients. One hundred eighty-five patients had a
single-lung metastasis. Lymph node dissection was performed in
353 cases.
Results: After a mean follow-up of 34 months, 247 patients (43%)
had died. Multivariate analysis disclosed that completeness of re-
section (p 0.0001), patients with germ cell tumors (p 0.04), and
DFI 36 months (p  0.01) were also associated with a better
prognosis. The actuarial survival after complete metastasectomy was
74% at 2 years and 46% at 5 years.
Conclusions: We confirmed completeness of surgery, histology,
and DFI 36 months as independent prognostic factors. Number of
metastases, presence of lymph node metastases, surgical approach,
and number of metastasectomies did not statistically influence long-
term survival.
Key Words: Lung metastasis, Surgery, Survival, Radicality, Mono-
center study.
(J Thorac Oncol. 2011;6: 1373–1378)
In 1990, Pastorino et al. established the International Reg-istry of Lung Metastases (IRLM), involving 18 major sur-
gical departments from Europe and North America (United
States and Canada). Throughout the metaanalysis, the registry
strengthened the idea that lung metastasectomy was poten-
tially curative and revealed that complete resectability, dis-
ease-free interval (DFI), and number of metastases were
independent prognostic factors.1
In recent decades, lung metastases have been consid-
ered an area of interest in many discussions between surgeons
and oncologists to identify the best therapeutic approach:
surgery, radiotherapy/chemotherapy, or all three? Improvements
in surgical technique and the development of more effective
chemotherapy regimens, which expanded the role of surgery,
gradually made lung metastasectomy a standard therapeutic
procedure in properly selected patients.2–5 To date, the selection
criteria have been complete control of the primary tumor, no
evidence of extrapulmonary metastases, the possibility for rad-
ical resection, and good respiratory function compatible with the
proposed lung resection procedure.1,6,7
Unfortunately, the lack of controlled trials and studies
limited by short follow-up and small cohorts have shed
doubts on the curative purpose of surgery in metastastic
patients. In addition, the heterogeneity of these patients in
terms of age, sex, primary tumor histology, staging system,
and surgical techniques could be a major limitation even in
the largest series.6–10 Even though a multicenter study could
be superior in terms of patient numbers and statistical anal-
ysis, it is not as good as in terms of group homogeneity.
This study analyzed our experience in the surgical
management of lung metastases to confirm and validate the
IRLM prognostic factors at the European Institute of Oncol-
ogy, Milan, Italy. Unlike most of the data reported so far, our
study was a single-center study, performed in the past 10
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years and up-to-date with all the modern staging systems to
minimize group heterogeneity and obtain better results.
PATIENTS AND METHODS
We retrospectively reviewed 575 patients who under-
went 708 lung metastasectomies with curative intent from
January 1998 to December 2008 at the Division of Thoracic
Surgery of the European Institute of Oncology, Milan, Italy.
Data were retrieved from individual medical records. All
patients included in the analysis had the primary tumor
controlled or controllable and no extrapulmonary metastases.
Suspected pulmonary metastatic lesions were evaluated dur-
ing pretreatment and tumor staging or during regular fol-
low-up after resection of primary tumor. All lung nodules
were identified according to the site of resection and histo-
pathologically analyzed. If histological analysis suggested a
possible primary lung cancer, the patients underwent pulmo-
nary lobectomy and radical lymphadenectomy, otherwise
lung resection was performed sparing as much of the lung
parenchyma as possible.
All 575 patients were investigated by computed tomog-
raphy (CT) scan. Three hundred sixty-seven patients were
also evaluated by positron emission tomography (PET)/CT
with fluorodeoxyglucose: increased glucose uptake in the
lung was evident in 318 patients, whereas the scan was
negative in 47 patients. None of the patients had extrathoracic
metastases. Twenty-one patients underwent preoperatory CT-
guided fine needle aspiration biopsy with a positive result in
17 cases, negative in 3 cases, and not diagnostic in 1 case.
Bronchoscopy was performed in 19 patients with lesions
situated near the tracheobronchial tree and was diagnostic in
four cases.
Despite the fact that all our patients were preoperatively
staged by whole-body CT scan, performed not later than 40
days from the surgery, 89 patients (15%) had an incomplete
resection because of unexpected pleural invasion or disease
progression after the first metastasectomy, which precluded
the possibility to perform the contralateral sequential surgery.
DFI was defined as the time between treatment of the
primary tumor and the diagnosis of metastases. One hundred
patients (17.3%) had a DFI of 0 to 12 months, 206 (36%) had
a DFI of 12 to 36 months, and 269 (46.7%) had a DFI of 36
months or more.
Two hundred nine patients had a single-lung metasta-
sis, and 366 had multiple lesions. According to the median of
resected metastases, patients were divided into 3 groups: a
single lesion in 209 cases (36.3%), 2 to 3 lesions in 200 cases
(34.8%), and 4 or more lesions in 166 cases (28.9%).
Metastasectomy was performed by thoracoscopy in 17
cases (3%) and open surgery in 558 cases (97%). Lymph
node dissection or sampling was performed in 374 cases.
During lung metastasectomy, the lymphadenectomy was not
routinely performed in our group; most of the patients had
just a sampling or diagnostic assessment and not a full nodal
dissection. This decision was usually based on the surgeon’s
discretion (preoperative or based on the macroscopical evi-
dence of lymph node involvement). Some patients received
chemotherapy based on the oncologist’s evaluation: 273 pa-
tients (47%) before surgical resection of the lung nodules and
177 patients (31%) after surgery.
Statistical Analysis
Survival estimates were calculated with Kaplan-
Meier’s method and compared by the log-rank test. Overall
survival was defined as the time between date of first metas-
tasectomy and the last follow-up or death. Multivariate Cox
proportional hazard regression analysis was used to assess the
independent prognostic significance of various clinical and
histopathological characteristics of the tumor on survival.
Factors included in multiple regression analyses were com-
pleteness of surgery, age, sex, DFI, histology, type of inter-
vention and access, and nodal status. All analyses were
performed with the SAS software (Cary, NC). All tests were
two sided.
RESULTS
After a mean follow-up of 34 months, 247 patients
(43%) had died (Figure 1A). Complete curative resection was
achieved in 490 patients (85%). Survival of patients with
incomplete resection was significantly poorer than that of
patients for whom resection was complete (p  0.0001;
Figure 1B). Therefore, we limited the presentation of the
FIGURE 1. Overall survival for all
patients (A) and according to com-
pleteness of pulmonary resection
(B) after a mean follow-up of 34
months.
Casiraghi et al. Journal of Thoracic Oncology • Volume 6, Number 8, August 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer1374
analysis of predictors of survival to patients with complete
resection.
Two hundred forty-seven were men and 328 were
women. Mean age was 58 years (range 14–83 years). Pri-
mary tumors were classified into four histological categories:
epithelial, sarcoma, melanoma, and germ cell tumors. Three
hundred seventy-two patients (76%) developed metastases
from epithelial tumors, 80 (16.3%) developed from sarcoma,
27 (5.5%) developed from melanoma, and 11 (2.2%) devel-
oped from germ cell tumors.
For each patient, we specified the histology of the
primary tumor according to the completeness of resection
(epithelial, sarcoma, melanoma, and germ cell tumors) and
the anatomical site of the epithelial tumors in detail (Table 1).
Three hundred ninety-seven patients (81%) underwent
a single procedure (including bilateral planned sequential
thoracotomies within 30 days), and 93 patients (19%) under-
went multiple metastasectomies (redo surgery or controlateral
surgery but later than 30 days). Three hundred thirty-seven
patients (68.8%) underwent monolateral thoracotomy, 129
(26.3%) bilateral planned thoracotomies, 10 (2%) median
sternotomy, 1 (0.2%) hemi clamshell, and 2 (0.4%) transma-
nubrial access. One hundred two (20.8%) patients underwent
tumorectomy by electrocautery, 192 (39.2%) wedge resec-
tion, and 58 (11.8%) segmentectomy. Lobectomy/bilobec-
tomy was performed in 132 patients (27%) and pneumonec-
tomy in 6 (1.2%) patients; in addition to pulmonary resection,
2 patients needed chest wall resection, and in another case,
diaphragm resection was performed.
Nodal metastases were detected in 62 cases (12.7%); in
291 cases (59.4%), nodes were negative. Lymphadenectomy
was not performed in 137 cases. Minor postoperative com-
plications were reported in 61 patients (12.4%): 25 patients
developed anemia, 20 atrial fibrillation, 17 air leak, 5 pneu-
monia, and 3 low-grade respiratory insufficiency. Major com-
plications occurred in seven patients (1.4%): five patients
developed hemothorax (requiring three rethoracotomies), one
patient developed chylothorax, and one patient developed
bronchopleural fistula (treated by rethoracotomy). There were
no postoperative deaths. Mean hospital stay after surgery was
5 days (range 2–36 days). Admission to intensive care unit
was necessary in 104 patients, with a mean stay of 1 day
(range 1–9 days).
The actuarial survival after complete metastasectomy
was 74% (95% confidence interval 70–79) at 2 years and
46% (95% confidence interval 41–52) at 5 years (Figure 1B).
One-, 2-, 5-, and 10-year actuarial survival according to
lymph node metastases, histology, number of metastasis, and
DFI are shown in Figures 2 and 3. Overall survival for 370
patients with completely resected pulmonary metastasis orig-
inating from an epithelial tumor according to anatomical site
of the primary tumor showed no statistical differences.
Overall survival according to PET and chemotherapy is
shown in Figures 4A, B. In both cases, the difference in
survival was not statistically significant. To accurately weigh
the real power of each prognostic factor, multivariate analysis
was performed on the whole series of patients (n  575) and
adjusted for completeness of surgery (Table 2).
Multivariate analysis confirmed that patients with germ
cell tumors (p  0.04) had a better prognosis, and those with
sarcoma (p  0.008) or melanoma (p  0.0001) had a
worse prognosis than those with epithelial tumors. DFI
36 months (p  0.01) was also associated with better
outcomes. Age, sex, chemotherapy, number of metastases,
presence of lymph node metastases, open surgery ap-
proach, and number of metastasectomies did not statisti-
cally influence long-term survival.
DISCUSSION
In the past, pulmonary metastases were considered fatal
in less than 2 years11,12 and had no indication for surgical
treatment. Since 1927, when Davis described the first inten-
tional lung metastasectomy, many case reports have shown
that surgical resection of lung metastases could improve
survival in selected patients.13,14 In 1947, Alexander and
Haight15 were the first to report a series of patients and
launched the preliminary selection criteria for lung metasta-
sectomy with curative intent: good performance status, ab-
sence of extra pulmonary metastases, and good control of the
primary tumor. Since then, more than 400 publications have
confirmed these selection criteria. Between 1940 and 1980,
the Mayo Clinic and Memorial Sloan-Kettering series
deemed the most significant experiences in the literature
given the large number of patients studied, emphasized the
curative value of surgery in the treatment of metastatic
lung disease showing a significant improvement in sur-
vival, and the importance of limited resections for salvage
iterative surgery.16,17
In 1990, Pastorino et al.1 established the IRLM, and
5206 pulmonary metastasectomies of various primary tumors
were enrolled to create a database and exchange information
with major thoracic surgery centers in Europe and the United
States. This also served for a homogeneous analysis of the
TABLE 1. Histology of Primary Tumors and Anatomical Site
of Epithelial Primary Tumors According to Completeness of
Pulmonary Resection
Histology of Primary Tumor All
Completeness
of Resection
R1 R0, n (%)
All 575 85 490 (85)
Epithelial 436 64 372 (85)
Sarcoma 94 14 80 (85)
Melanoma 33 6 27 (82)
Germ cell tumorsa 12 1 11 (92)
Epithelial
Gastrointestinal 210 23 187 (89)
Breast 51 8 43 (84)
Urothelial 86 15 71 (83)
Gynecological 42 5 37 (88)
Head-neck 43 13 30 (70)
Thymus 4 — 4 (100)
a Germ cell tumors include includes six teratocarcinoma, four chorioncarcinoma,
and two yolk sac tumors.
R0, complete resection; R1, incomplete resection.
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results to glean prognostic criteria and other information on
this type of surgery. Throughout the metaanalysis, the regis-
try strengthened the idea that lung metastasectomy was po-
tentially curative, showing that survival after complete me-
tastasectomy (R0) was 36% at 5 years, 26% at 10 years, and
22% at 15 years compared with survival after incomplete
resection (R1), which was 13% at 5 years and 7% at 10 years.
In addition, multivariate analysis revealed that complete re-
sectability, DFI, and number of metastases were independent
prognostic factors.1
The IRLM was exhaustive in terms of patient identifi-
cation, description of the primary tumor, metastasectomy
performed, and follow-up but lacked information on preop-
erative staging of patients, which we think as one of the most
important steps for optimal patient selection and conse-
quently a homogeneous database.18 All patients in our 10-
year monocenter study underwent total body CT scan, and
since 2002, all patients (316/575) have had PET/CT as
preoperative staging.
Our retrospective study is based on a surgical database,
and survival was calculated from the date of metastasectomy,
regardless of any prior treatment. Therefore, for the 239
patients who received neoadjuvant chemotherapy, overall
survival calculated from the date of surgery may be under-
estimated and not strictly comparable with that of patients
treated with different modalities. Despite that we showed no
difference in survival for patients who received neoadjuvant
chemotherapy or not. Conversely, our study cannot give any
unbiased answer on the potential benefit of neoadjuvant
chemotherapy in patients with lung metastasis amenable to
surgery.
After a mean follow-up of 34 months, the overall
survival of patients after a complete resection was 74% at 2
years and 46% at 5 years showing a highly statistically
FIGURE 2. Overall survival according to disease-free interval (A), lymph node involvement (B), histology (C), and epithelial
tumors subtypes (D).
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significant difference (p 0.0001) compared with the overall
survival for patients with incomplete resection (47% overall
survival at 2 years and 20% at 5 years). For this reason, our
observational and statistic analysis was confined to patients
who had radical surgery.
The 5-year survival rate (46%) is surprising considering
both the type of surgery and previous literature data. We
believe that this survival rate is the result of better patient
selection because of a homogeneous database (monocenter
study) and the use of modern staging systems (CT scan and
CT/PET), which allowed us to check all patients preopera-
tively and eventually exclude them from surgery if extratho-
racic or other tumor localizations were found.
In line with the IRLM, we found that primary tumor
histology affected the outcome of metastasectomies. Multi-
variate analysis showed significantly better survival rates for
patients with germ cell tumors (p  0.03) compared with
epithelial tumors. The good survival of patients with germ
cell tumor may be due to the presurgical chemotherapy and
the treatment of choice for these tumors more than the
surgery itself: 9 of 11 patients with germ cell tumor had a
complete pathological response in the histopathology speci-
men. Even though sarcomas have a worse prognosis than
other tumors, the patients’ long-term survival justifies the
surgery approach. A possible improvement may be achieved
by selecting sarcomas according to different subtypes, but
this analysis is a part of another ongoing work. Analyzing the
epithelial tumors in detail, we failed to disclose survival
differences for the different subtypes (Figure 2B).
Similar to the study by Pastorino et al.,1 our multivar-
iate analysis also showed that DFI less than 12 months
(patients with synchronous metastases) was an independent
prognostic factor with an overall survival of 59% at 2 years
and 49% at 5 years compared with a DFI longer than or equal
to 36 months (p  0.01).
Despite IRLM, the number of metastases treated was
not statistically significant (p  0.64) even if this does have
some influence on survival. The overall survival was 74% at
2 years and 45% at 5 years for patients with only one
metastasis compared with patients with more than four (66%
survival at 2 years and 44% at 5 years).
Pastorino et al. showed in the registry that multiple
metastasectomies were related to a very good survival (44%
survival compared with 34% for patients who had only one
metastasectomy). In disagreement with the IRLM results, we
did not find that the number of lung metastasectomies af-
fected survival (Figure 3). Because the probability of devel-
oping subsequent lung metastases is greater among long-term
survivors, we could only perform this analysis starting from
the date of the last lung metastasectomy and stratify patients
according to the number of previous metastasectomies but
found no survival difference between groups. Although based
FIGURE 3. Overall survival according to number of pulmo-
nary metastasectomies after the last complete resection.
FIGURE 4. Overall survival ac-
cording to positron emission to-
mography (PET) (A) and chemo-
therapy (CT) (B).
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on limited numbers, in our series, video-assisted thoracosopic
surgery led to incomplete resections in a higher proportion of
cases than open surgery (p  0.03). Even though this is a
matter of controversy, we firmly believe that open surgery is
essential for the treatment of metastases to be able to finger
the lung parenchyma and not to miss any small metastatic
foci that could have escaped the preoperative CT scan. In this
connection, several authors recently published data showing
that 37% of patients presented more nodules during thoracot-
omy than the number identified by CT scan.19–21
In conclusion, our 10-year single-center experience
confirmed completeness of the resection, histology, and DFI
as independent prognostic factors identifying a group of
patients who may benefit from pulmonary metastasectomy.
Compared with IRLM, the number of metastases and surgical
interventions were not significant and associated with an
increase in survival. The homogeneity of patient’s selection
and a complete preoperative staging are essential for good
long-term survival.
REFERENCES
1. Pastorino U, Buyse M, Friedel G, et al. Long term results of lung
metastasectomy: prognostic analysis based on 5206 cases. J Thoracic
Cardiovasc Surg 1997;113:37–49.
2. Martini N, McCormack PM. Evolution of the surgical management of
pulmonary metastases. Chest Surg Clin N Am 1998;8:13–27.
3. Jaffe N, Smith E, Abelson HT, et al. Osteogenic sarcoma: alteration in
the pattern of pulmonary metastases with adjuvant chemotherapy. J Clin
Oncol 1983;1:251–254.
4. Potter DA, Glenn J, Kinsella T, et al. Patterns of recurrence in patients
with high-grade soft-tissue sarcomas. J Clin Oncol 1985;3:353–366.
5. Goya T, Miyazawa N, Kondo H, et al. Surgical resection of pulmonary
metastases from colorectal cancer: 10 year follow-up. Cancer 1989;64:
1418–1421.
6. Marincola FM, Mark JB. Selection factors resulting in improved sur-
vival after surgical resection of tumors metastatic to the lungs. Arch Surg
1990;125:1387–1392; discussion 1392–1393.
7. Girard P, Baldeyrou P, Le Chevalier T, et al. Surgery for pulmonary
metastases. Who are 10-year survivors? Cancer 1994;74:2791–2797.
8. Putnam JB Jr, Roth JA. Prognostic indicators in patients with pulmonary
metastases. Semin Surg Oncol 1990;6:291–296.
9. Mountain CF, McMurtrey MJ, Hermes KE. Surgery for pulmonary
metastasis: a 20-year experience. Ann Thorac Surg 1984;38:323–330.
10. Venn GE, Sarin S, Goldstraw P. Survival following pulmonary metas-
tasectomy. Eur J Cardiothorac Surg 1989;3:105–109; discussion 110.
11. McKenna RJ, McKenna RJ Jr. Patterns of pulmonary metastases. An
orthopedic hospital experience. In Weiss L, Gilbert HA (Eds.), Pulmo-
nary Metastasis. Boston, GK: Hall & Co, 1978; 1626–1634.
12. McCormack PM, BainsMS,Martini N. Surgical management of pulmonary
metastases. In Shiu M, Brennan M (Eds.), Surgical Management of Soft
Tissue Sarcoma. Philadelphia, PA: Lea & Febinger, 1989; 70–77.
13. Edwards AT. Malignant disease of the lung. J Thorac Surg 1934;4:107–
124.
14. Barney JD, Churchill ED. Adenocarcinoma of the kidney with metas-
tases to the lung cured by nephrectomy and lobectomy. J Urol 1939;42:
269–276.
15. Alexander J, Haight C. Pulmonary resection for solitary metastatic
sarcomas and carcinomas. Surg Gynecol Obstet 1947;85:129–146.
16. Thomford NR, Woolner LB, Clagett OT. The surgical treatment of
metastatic tumors in the lungs. J Thorac Cardiovasc Surg 1965;49:357–
363.
17. McCormack PM, Martini N. The changing role of surgery for pulmonary
metastases. Ann Thorac Surg 1979;28:139–145.
18. Pastorino U, Veronesi G, Landoni C, et al. Fluorodeoxyglucose positron
emission tomography improves preoperative staging of resectable lung
metastasis. J Thorac Cardiovasc Surg 2003;126:1906–1910.
19. Cerfolio RJ, Bryant AS. Is palpation of the nonresected pulmonary
lobe(s) required for patients with non-small cell lung cancer? A pro-
spective study. J Thorac Cardiovasc Surg 2008;131:261–268.
20. Kayton ML, Huvos AG, Casher J, et al. Computed tomographic scan of
the chest understimates the number of metastatic lesions in osteosar-
coma. J Pediatr Surg 2006;41:200–206.
21. Mutsaert EL, Zoetmulder FA, Meijer S, et al. Outcome of thoracoscopic
pulmonary metastasectomy evaluated by confirmatory thoracotomy. Ann
Thorac Surg 2001;72:230–233.
TABLE 2. Multivariate Analysis for Overall Survival after
Pulmonary Metastasectomy
Variable HR (95% CI) p
Resection
R0 1.00
R1 2.49 (1.72–3.61) 0.0001
DFI
Simultaneous 0.07 (0.01–0.50) 0.009
1–12 mo 1.00
12–36 mo 0.81 (0.56–1.18) 0.27
36 mo 0.60 (0.41–0.87) 0.01
Sex
Men 1.00
Women 1.02 (0.78–1.33) 0.89
Age (yr)
60 1.00
60–69 1.33 (0.98–1.80) 0.07
70–79 1.10 (0.76–1.59) 0.63
80 1.71 (0.41–7.08) 0.46
Metastasis
1 1.00
2–3 1.11 (0.81–1.52) 0.53
4 1.19 (0.79–1.80) 0.41
Histology
Epithelial 1.00
Sarcoma 1.74 (1.26–2.40) 0.0008
Melanoma 3.26 (1.99–5.33) 0.0001
Germ cell 0.12 (0.02–0.87) 0.04
Surgery
Wedge/segmentectomy 1.00
Lobectomy/bilobectomy 1.21 (0.84–1.75) 0.31
Other 1.01 (0.36–2.82) 0.98
Bilateral 1.02 (0.67–1.54) 0.93
Access
Open 1.00
VATS 1.27 (0.57–2.84) 0.56
Nodal status
Negative 1.00
Positive 1.37 (0.91–2.05) 0.13
Unknown 1.00 (0.73–1.39) 0.99
HR and 95% CIs obtained form Cox proportional hazards regression model.
Statistically significant p values are given in bold.
R0, complete resection; R1, incomplete resection; DFI, disease-free interval;
VATS, video-assisted thoracosopic surgery; CI, confidence interval; HR, hazards ratios.
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